期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

格列卫治疗19例慢性粒细胞性白血病急变期患者疗效观察

下载PDF
导出
作者 杨国华 沈云峰 毛玉文
机构地区 江苏省无锡市第一人民医院血液科
出处 《实用临床医药杂志》 CAS 2006年第3期85-86,共2页 Journal of Clinical Medicine in Practice
关键词 格列卫 慢性粒细胞性白血病 急变期 伊马替尼 PH染色体 肿瘤靶面治疗
分类号 R733.7 [医药卫生—肿瘤]
  • 相关文献

参考文献6

  • 1Faded S, Kantarjian H M, Talpaz M. Chronic mydogenous leukemia[J]. Oneology, 1999, 13. 169.
  • 2Druker B J, Talpaz M, Resta D J, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia[J]. N Engl J Med, 2001, 344(14): 1031.
  • 3金正明,吴德沛,孙爱宁,仇惠英,唐晓文.伊马替尼治疗Ph阳性慢性髓细胞白血病急变期及急性淋巴细胞白血病39例[J].实用临床医药杂志,2005,9(8):53-54. 被引量：11
  • 4Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and eytogenetie responses to imatinib mesylate in chronic myclogenous leukemia[J]. N Engl J Med, 2002, 346(9): 645.
  • 5Bhatia R, Holtzl M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients on complete eytogenetic remission following imatinib mesylate treatment[J]. Blood, 2003, 101(12): 4701.
  • 6Thambi P, Sausville E A. STI571 (imatinib mesylate): the tale of t targeted therapy[J]. Antieaneer Drugs, 2002, 13(2): 111.

二级参考文献10

  • 1Druker B J, Talpaz M, Resta D J, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia [J]. N Engl J Med, 2001, 344: 1031.
  • 2Goldman J M, Melo J V. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia [J]. N Engl J Med, 2001, 344: 1084.
  • 3Druker B J, Sawyers C L, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome [J]. N Engl J Med, 2001, 344: 1038.
  • 4Talpaz M, Silver R T, Druker B J, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid 1eukemia: results of a phase2 study [J]. Blood, 2002, 99: 1928.
  • 5Sawyers C L, Hochhaus A, Feldman E, et al. Imatinib mesylate induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase Ⅱ study [J]. Blood, 2002, 99: 3530.
  • 6Ottmann O G, Druker B J, Sawyers C L, et al. A phase Ⅱ study of imatinib Mesylate (Gleevec) in patients with relapsed or refractory Philadelphia chromosome positive acute lymphoid leukemia [J]. Blood, 2002, 100: 1965.
  • 7Sacchi S, Kantarjian H M, O'Brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients [J]. Cancer, 1999, 86: 2632.
  • 8Walters R S, Kantarjian H M, Keating M J, et al. Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron [J]. Cancer, 1987, 60: 1708.
  • 9Copelan E A, Mcguire E A. The biology and treatment of acute 1ymphoblastic leukemia in adults [J]. Blood, 1995, 85: 1151.
  • 10C1ift R A, Storb R. Marrow transplantation for CML: the Seattle experience [J]. Bone Marrow Transplant, 1996, 17(Suppl 3): S1.

共引文献10

实用临床医药杂志
2006年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部